- Home
- SQFT vs CERO Comparison
SQFT vs CERO Comparison
Compare SQFT & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQFT
- CERO
- Stock Information
- Founded
- SQFT 1999
- CERO 2017
- Country
- SQFT United States
- CERO United States
- Employees
- SQFT N/A
- CERO N/A
- Industry
- SQFT Real Estate Investment Trusts
- CERO
- Sector
- SQFT Real Estate
- CERO
- Exchange
- SQFT Nasdaq
- CERO Nasdaq
- Market Cap
- SQFT 6.2M
- CERO 3.5M
- IPO Year
- SQFT 2020
- CERO N/A
- Fundamental
- Price
- SQFT $5.15
- CERO $8.90
- Analyst Decision
- SQFT
- CERO Strong Buy
- Analyst Count
- SQFT 0
- CERO 2
- Target Price
- SQFT N/A
- CERO $45.00
- AVG Volume (30 Days)
- SQFT 12.6K
- CERO 3.3M
- Earning Date
- SQFT 08-13-2025
- CERO 08-13-2025
- Dividend Yield
- SQFT N/A
- CERO N/A
- EPS Growth
- SQFT N/A
- CERO N/A
- EPS
- SQFT N/A
- CERO N/A
- Revenue
- SQFT $18,260,398.00
- CERO N/A
- Revenue This Year
- SQFT $23.63
- CERO N/A
- Revenue Next Year
- SQFT N/A
- CERO N/A
- P/E Ratio
- SQFT N/A
- CERO N/A
- Revenue Growth
- SQFT N/A
- CERO N/A
- 52 Week Low
- SQFT $4.19
- CERO $6.71
- 52 Week High
- SQFT $8.77
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- SQFT 51.05
- CERO 46.23
- Support Level
- SQFT $4.55
- CERO $8.50
- Resistance Level
- SQFT $5.77
- CERO $9.73
- Average True Range (ATR)
- SQFT 0.37
- CERO 1.20
- MACD
- SQFT 0.09
- CERO -0.01
- Stochastic Oscillator
- SQFT 56.96
- CERO 14.54
About SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.